Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions

Chest

Volumn 146, Issue 6, 2014, Pages 1251-1257

  De Strooper, Lise M A ^a   Meijer, Chris J L M ^a   Berkhof, Johannes ^a   Hesselink, Albertus T ^a   Snijders, Peter J F ^a   Steenbergen, Renske D M ^a   Heideman, Daniëlle A M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DISEASE SEVERITY; DNA METHYLATION; FAM19A4 GENE; FEMALE; GENE; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METHYLATION POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VALIDATION STUDY; ADOLESCENT; CANCER DIAGNOSIS; CONDYLOMA ACUMINATUM; METHYLATION; PRIORITY JOURNAL; UTERINE CERVIX CYTOLOGY;

EID: 84938094491     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0237     Document Type: Article

References (38)

1. Zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl cancer Inst 2000;92:690-8.
2. Snijders PJF, Steenbergen RDM, Heideman DAM, Meijer CJLM. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152-64.
3. Steenbergen RDM, Snijders PJF, Heideman DAM, Meijer CJLM. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014;14:395-405.
4. Saavedra KF, Brebi PS, Roa JC. Epigenetics alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenetics 2012;4:13.
5. Steenbergen RDM, Kramer D, Braakhuis BJM, Stern PL, Verheijen RHM, Meijer CJLM, et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 2004;96:294-305.
6. Wilting SM, van Boerdonk RAA, Henken FE, Meijer CJLM, Diosdado B, Meijer GA, et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer 2010;9:167.
7. Overmeer RM, Henken FE, Snijders PJF, Claassen-Kramer D, Berkhof J, Helmerhorst TJM, et al. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol 2008;1:388-97.
8. Overmeer RM, Henken FE, Bierkens M, Wilting SM, Timmerman I, Meijer CJLM, et al. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol 2009; 219:327-36.
9. Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM. Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int 2013;2013:519619.
10. Hesselink AT, Heideman DAM, Steenbergen RDM, Gok M, van Kemenade FJ, Wilting SM, et al. Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer 2014;135: 880-6.
11. Hesselink AT, Heideman DAM, Steenbergen RDM, Coupe VMH, Overmeer RM, Rijkaart D, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011;17:2459-65.
12. Verhoef VMJ, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DAM, Hesselink AT, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol 2014;15:315-22.
13. Eijsink JJH, Lendvai A, Deregowski V, Klip HG, Verpooten G, Dehaspe L, et al. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer 2012;130: 1861-9.
14. Huang T-H, Lai H-C, Liu H-W, Lin CJ, Wang K-H, Ding D-C, et al. Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer. Int J Gynecol Cancer 2010;20:513-9.
15. Eijsink JJH, Yang N, Lendvai A, Klip HG, Volders HH, Buikema HJ, et al. Detection of cervical neoplasia by DNA methylation analysis in cervicovaginal lavages, a feasibility study. Gynecol Oncol 2011;120:280-3.
16. Bierkens M, Hesselink AT, Meijer CJLM, Heideman DAM, Wisman GBA, van der Zee AGJ, et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer 2013;133:1293-9.
17. De Strooper LMA, Hesselink AT, Berkhof J, Meijer CJLM, Snijders PJF, Steenbergen RDM, et al. Combined CADM1/MAL methylation and cytology testing for colposcopy triage of high-risk HPV-positive women. Cancer Epidemiol Biomarkers Prev 2014;23:1933-7.
18. Hansel A, Steinbach D, Greinke C, Schmitz M, Eiselt J, Scheungraber C, et al. A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women. PLoS One 2014;9: e91905.
19. Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J, Szarewski A, et al. A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. Int J Cancer 2014;135:1425-32.
20. Steenbergen RDM, Ongenaert M, Snellenberg S, Trooskens G, van der Meide WF, Pandey D, et al. Methylation-specific digital karyotyping of HPV16E6E7 expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis. J Pathol 2013;231:53-62.
21. Cook DN. The role of MIP-1α and hematopoiesis. J Leucoc Biol 1996;59:61-6.
22. Bulkmans NWJ, Rozendaal L, Snijders PJF, Voorhorst FJ, Boeke AJP, Zandwijken GRJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101.
23. Bulkmans NWJ, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJP, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72.
24. Hesselink AT, Bulkmans NWJ, Berkhof J, Lorincz AT, Meijer CJLM, Snijders PJF. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol 2006;44:3680-5.
25. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJLM. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004;57: 388-93.
26. oncoline.nl [Internet]. Integraal Kankercentrum Nederland; 2014 [updated 2014; cited 2014 Jun 26]. Available from: www.oncoline.nl
27. Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol 2010;171:155-63.
28. Bierkens M, Wilting SM, van Wieringen WN, van Kemenade FJ, Bleeker MCG, Jordanova ES, et al. Chromosomal profiles of high-grade cervical intraepithelial neoplasia relate to duration of preceding high-risk human papillomavirus infection. Int J Cancer 2012;131: E579-85.
29. Snellenberg S, De Strooper LMA, Hesselink AT, Meijer CJLM, Snijders PJF, Heideman DAM, et al. Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape. BMC Cancer 2012;12:551.
30. Kan Y-Y, Liou Y-L, Wang H-J, Chen C-Y, Sung L-C, Chang C-F, et al. PAX1 methylation as a potential biomarker for cervical cancer screening. Int J Gynecol Cancer 2014;24:928-34.
31. Lin H, Chen T-C, Chang T-C, Cheng Y-M, Chen C-H, Chu T-Y, et al. Methylated ZNF582 gene as a marker for triage of women with Pap smear reporting low-grade squamous intraepithelial lesions - A Taiwanese Gynecologic Oncology Group (TGOG) study. Gynecol Oncol 2014 Aug 16. [Epub ahead of print].
32. Rebolj M, van Ballegooijen M, Berkers L-M, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007; 120:806-12.
33. Gok M, Heideman DAM, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JWM, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010;340:c1040.
34. Gok M, Heideman DAM, van Kemenade FJ, de Vries ALM, Berkhof J, Rozendaal L, et al. Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: characteristics of the responders. Eur J Cancer 2012;48:1799-808.
35. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmeron J, Uribe P, Velasco-Mondragon E, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011;378: 1868-73.
36. Giorgi Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br J Cancer 2011;104:248-54.
37. Snijders PJF, Verhoef VMJ, Arbyn M, Ogilvie G, Minozzi S, Banzi R, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 2013;132: 2223-36.
38. Gyllensten U, Sanner K, Gustavsson I, Lindell M, Wikstrom I, Wilander E. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer. Br J Cancer 2011;105:694-97.